Blurbs

Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Oncternal Therapeutics (ONCT) and Curis (CRIS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAVResearch Report), Oncternal Therapeutics (ONCTResearch Report) and Curis (CRISResearch Report) with bullish sentiments.

Aravive (ARAV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive today and set a price target of $26.00. The company’s shares closed last Friday at $1.21, close to its 52-week low of $1.02.

According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -29.4% and a 19.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.

Aravive has an analyst consensus of Strong Buy, with a price target consensus of $16.67.

See Insiders’ Hot Stocks on TipRanks >>

Oncternal Therapeutics (ONCT)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oncternal Therapeutics, with a price target of $8.00. The company’s shares closed last Friday at $1.52, close to its 52-week low of $0.69.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -42.1% and a 12.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Aquestive Therapeutics, and Oramed Pharmaceuticals.

Oncternal Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.70, a 480.0% upside from current levels. In a report issued on May 27, Northland Securities also maintained a Buy rating on the stock with a $15.00 price target.

Curis (CRIS)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Curis, with a price target of $16.00. The company’s shares closed last Friday at $0.94, close to its 52-week low of $0.70.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.3% and a 20.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Currently, the analyst consensus on Curis is a Strong Buy with an average price target of $9.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARAV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos